SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-20-006741
Filing Date
2020-05-15
Accepted
2020-05-15 16:31:29
Documents
44
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q apre-20200331x10q.htm 10-Q 1545009
2 EX-31.1 apre-20200331ex31150ff04.htm EX-31.1 11023
3 EX-31.2 apre-20200331ex31265edf9.htm EX-31.2 11014
4 EX-32.1 apre-20200331ex321c8e5ff.htm EX-32.1 7716
5 EX-32.2 apre-20200331ex322f70447.htm EX-32.2 7709
  Complete submission text file 0001558370-20-006741.txt   3146066

Data Files

Seq Description Document Type Size
6 EX-101.INS apre-20200331.xml EX-101.INS 324335
7 EX-101.SCH apre-20200331.xsd EX-101.SCH 22386
8 EX-101.CAL apre-20200331_cal.xml EX-101.CAL 31009
9 EX-101.DEF apre-20200331_def.xml EX-101.DEF 41482
10 EX-101.LAB apre-20200331_lab.xml EX-101.LAB 200226
11 EX-101.PRE apre-20200331_pre.xml EX-101.PRE 136909
Mailing Address 535 BOYLSTON STREET BOSTON MA 02116
Business Address 535 BOYLSTON STREET BOSTON MA 02116 6095104718
Aprea Therapeutics, Inc. (Filer) CIK: 0001781983 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39069 | Film No.: 20885918
SIC: 2834 Pharmaceutical Preparations